Fondaparinux
Fondaparinux, sold as Arixtra, is an anticoagulant of the Factor Xa inhibitor type, given by injection under the skin. The US label read lists, in adults, prophylaxis of deep vein thrombosis in people having hip fracture, hip replacement, knee replacement or abdominal surgery, and treatment of acute deep vein thrombosis or acute pulmonary embolism when given with warfarin sodium. It also lists treatment of venous thromboembolism in children aged 1 year or older who weigh at least 10 kg. The label carries a boxed warning about epidural or spinal hematomas in people who are anticoagulated and have neuraxial anesthesia or a spinal puncture.
Also called Arixtra · Fondaparinux sodium
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 321208; UNII X0Q6N9USOZ is the UNII of fondaparinux sodium, the form the label names, and is a broad match. MeSH descriptor D000077425 is Fondaparinux. Class: Factor Xa Inhibitor (FDA established pharmacologic class, RxClass); the label also writes (anticoagulant) after the class name. The label read is the Mylan Institutional LLC label for Arixtra, application NDA021345, effective 2024-12-10 in openFDA. Adult and paediatric statements are kept in separate contexts and claims. This page records label indications, the first sentence of the boxed warning and the class only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says fondaparinux, through antithrombin III, selectively inhibits Factor Xa, which interrupts the blood coagulation cascade.
Classification codes
-
X0Q6N9USOZ
Claims and evidence
Context Adults for whom the US label of fondaparinux (Arixtra) lists an indication: prophylaxis of deep vein thrombosis after hip fracture, hip replacement, knee replacement or abdominal surgery; treatment of deep vein thrombosis or acute pulmonary embolism
- Recipient
- Adult
- Population
- Adult patients described in the indications sections of the label.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Adults, as the passages read state
- Follow-up
- Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Adult patients undergoing hip fracture surgery, hip replacement surgery, knee replacement surgery or abdominal surgery, for prophylaxis of deep vein thrombosis
- Adult patients with deep vein thrombosis or acute pulmonary embolism, when administered in conjunction with warfarin sodium
- Excluded
- None stated
The US label of Arixtra (fondaparinux sodium), in the Mylan Institutional LLC version dated 2024-12-10 in openFDA, describes fondaparinux as a Factor Xa inhibitor (anticoagulant) and lists it, in adult patients, for the prophylaxis of deep vein thrombosis in patients undergoing hip fracture surgery, hip replacement surgery, knee replacement surgery or abdominal surgery, and for the treatment of deep vein thrombosis or acute pulmonary embolism when administered in conjunction with warfarin sodium. The label carries a boxed warning about epidural or spinal hematomas in anticoagulated patients who receive neuraxial anesthesia or undergo spinal puncture.
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for in adults. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The paediatric indication is recorded in a separate claim. Only the indications, the first sentence of the boxed warning and the mechanism sentence were read; contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA also lists generic labels. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (5)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (LB-04).
- Retrieved
- Source effective date
- 2024-12-10
- Source state
- Current
- Version fingerprint
1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE, first bullet
- How it applies
- Label passage quoted in the research quote table (LB-05).
- Retrieved
- Source effective date
- 2024-12-10
- Source state
- Current
- Version fingerprint
1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE, second bullet
- How it applies
- Label passage quoted in the research quote table (LB-06).
- Retrieved
- Source effective date
- 2024-12-10
- Source state
- Current
- Version fingerprint
1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], sentence 1
- How it applies
- Label passage quoted in the research quote table (LB-08).
- Retrieved
- Source effective date
- 2024-12-10
- Source state
- Current
- Version fingerprint
1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20241210.
- Retrieved
- Source effective date
- 2024-12-10
- Source state
- Current
- Version fingerprint
1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context Children for whom the US label of fondaparinux (Arixtra) lists an indication: venous thromboembolism in pediatric patients aged 1 year or older weighing at least 10 kg
- Recipient
- Child
- Population
- Pediatric patients aged 1 year or older who weigh at least 10 kg, as the label states.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Children aged 1 year or older, as the passage read states
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Pediatric patients aged 1 year or older weighing at least 10 kg, with venous thromboembolism
- Excluded
- None stated
The US label of Arixtra (fondaparinux sodium), in the Mylan Institutional LLC version dated 2024-12-10 in openFDA, lists the medicine for the treatment of venous thromboembolism in pediatric patients aged 1 year or older weighing at least 10 kg.
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label's paediatric use, dosing and safety sections were not read. The adult indications are recorded in a separate claim. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0], 1.4 Treatment of Venous Thromboembolism in Pediatric Patients
- How it applies
- Label passage quoted in the research quote table (LB-07).
- Retrieved
- Source effective date
- 2024-12-10
- Source state
- Current
- Version fingerprint
1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20241210.
- Retrieved
- Source effective date
- 2024-12-10
- Source state
- Current
- Version fingerprint
1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Pregnancy, lactation and children
The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.
In newborns, infants and children 1
The US label of Arixtra (fondaparinux sodium), in the Mylan Institutional LLC version dated 2024-12-10 in openFDA, lists the medicine for the treatment of venous thromboembolism in pediatric patients aged 1 year or older weighing at least 10 kg.
Applies to Child Children for whom the US label of fondaparinux (Arixtra) lists an indication: venous thromboembolism in pediatric patients aged 1 year or older weighing at least 10 kg
Population, setting and follow-up
- Pediatric patients aged 1 year or older who weigh at least 10 kg, as the label states.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Children aged 1 year or older, as the passage read states
- Gestational age Not reported
- Postnatal age Not reported
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label's paediatric use, dosing and safety sections were not read. The adult indications are recorded in a separate claim. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0], 1.4 Treatment of Venous Thromboembolism in Pediatric Patients
- How it applies
- Label passage quoted in the research quote table (LB-07).
- Retrieved
- Source effective date
- 2024-12-10
- Source state
- Current
- Version fingerprint
1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20241210.
- Retrieved
- Source effective date
- 2024-12-10
- Source state
- Current
- Version fingerprint
1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
ARIXTRA
No label from the application holder was found in the openFDA label dataset for application NDA021345. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists prophylaxis and treatment of deep vein thrombosis in adults as an indication: Deep vein thrombosis
The US label of Arixtra (fondaparinux sodium), in the Mylan Institutional LLC version dated 2024-12-10 in openFDA, describes fondaparinux as a Factor Xa inhibitor (anticoagulant) and lists it, in adult patients, for the prophylaxis of deep vein thrombosis in patients undergoing hip fracture surgery, hip replacement surgery, knee replacement surgery or abdominal surgery, and for the treatment of deep vein thrombosis or acute pulmonary embolism when administered in conjunction with warfarin sodium. The label carries a boxed warning about epidural or spinal hematomas in anticoagulated patients who receive neuraxial anesthesia or undergo spinal puncture.Limitations. This claim records what the label says the medicine is indicated for in adults. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The paediatric indication is recorded in a separate claim. Only the indications, the first sentence of the boxed warning and the mechanism sentence were read; contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA also lists generic labels. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists treatment of acute pulmonary embolism in adults, with warfarin sodium, as an indication: Pulmonary embolism
The US label of Arixtra (fondaparinux sodium), in the Mylan Institutional LLC version dated 2024-12-10 in openFDA, describes fondaparinux as a Factor Xa inhibitor (anticoagulant) and lists it, in adult patients, for the prophylaxis of deep vein thrombosis in patients undergoing hip fracture surgery, hip replacement surgery, knee replacement surgery or abdominal surgery, and for the treatment of deep vein thrombosis or acute pulmonary embolism when administered in conjunction with warfarin sodium. The label carries a boxed warning about epidural or spinal hematomas in anticoagulated patients who receive neuraxial anesthesia or undergo spinal puncture.Limitations. This claim records what the label says the medicine is indicated for in adults. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The paediatric indication is recorded in a separate claim. Only the indications, the first sentence of the boxed warning and the mechanism sentence were read; contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA also lists generic labels. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists treatment of venous thromboembolism in pediatric patients aged 1 year or older weighing at least 10 kg as an indication: Venous thromboembolism
The US label of Arixtra (fondaparinux sodium), in the Mylan Institutional LLC version dated 2024-12-10 in openFDA, lists the medicine for the treatment of venous thromboembolism in pediatric patients aged 1 year or older weighing at least 10 kg.Limitations. This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label's paediatric use, dosing and safety sections were not read. The adult indications are recorded in a separate claim. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 1
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 5 efficacy supplement approvals on record.
Record details
- Record id
cardio:fondaparinux- Content hash
18bb54ee39999d7b46238c5b0a04418e7ee8fd56fc78729e38a295662f0e2d15